CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Clinical trials for CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA GASTRIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study tests a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach cancer that has spread to the lining of the belly. The main goal is to find the safest dose and understand side effects. About 27 adults with this…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Immuno-Chemo-Radiation cocktail shows promise against stomach cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation before surgery can help treat stomach cancer that can be surgically removed. The trial includes 32 adults with early-stage stomach or gastroesophageal junction…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Shorter radiation before stomach cancer surgery shows promise in early trial
Disease control OngoingThis early-phase trial tests whether a shorter course of chemoradiation (2 weeks instead of 5) followed by standard chemotherapy is safe and effective for people with stomach cancer who will have surgery. About 25 participants will receive the shorter radiation along with chemo d…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
Immunotherapy combo shows promise for genetic stomach cancer subtype
Disease control OngoingThis study looks at whether an immunotherapy drug (atezolizumab) alone or combined with chemotherapy can help control a certain type of stomach or gastroesophageal junction cancer that has a genetic feature called MSI-H/dMMR. About 240 adults with localized or locoregional cancer…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Radiation boosts chemo for Limited-Stage esophageal and stomach cancer?
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with esophageal or stomach cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemo alone or chemo plus radiation. The goal i…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 16, 2026 22:53 UTC